CRYSTAL FORM OF ISOCHROMAN COMPOUND
A crystal form of an isochroman compound and a preparation method therefor. A compound as shown in formula (I) and an application of the compound in preparation of drugs for treating related diseases are specifically involved.
1 . A crystal form A of a compound of formula (I)
wherein the crystal form A of the compound of formula (I) has an X-ray powder diffraction pattern comprising characteristic diffraction peaks at the following 2θ angles: 8.25±0.20°, 19.21±0.20°, and 21.76±0.20° using Cu-Kα radiation.
2 . The crystal form A of the compound of formula (I) according to claim 1 , wherein the X-ray powder diffraction pattern thereof comprises characteristic diffraction peaks at the following 2θ angles: 8.25±0.20°, 13.27±0.20°, 15.19±0.20°, 16.43±0.20°, 17.94±0.20°, 19.21±0.20°, and 21.76±0.20°.
3 . The crystal form A of the compound of formula (I) according to claim 1 , wherein the X-ray powder diffraction pattern thereof comprises characteristic diffraction peaks at the following 2θ angles: 8.25±0.20°, 15.19±0.20°, 16.43±0.20°, 17.94±0.20°, 19.21±0.20°, 21.76±0.20°, 23.56±0.20°, and 26.66±0.20°.
4 . The crystal form A of the compound of formula (I) according to claim 3 , wherein the X-ray powder diffraction pattern thereof comprises characteristic diffraction peaks at the following 2θ angles: 8.25°, 12.56°, 12.89°, 13.27°, 15.19°, 16.01°, 16.43°, 17.60°, 17.94°, 19.21°, 19.91°, 20.21°, 20.52°, 21.25°, 21.76°, 23.02°, 23.56°, 24.71°, 25.12°, 25.88°, 26.66°, 27.10°, 27.43°, 27.84°, 28.38°, 29.13°, 30.01°, 30.83°, 31.69°, 32.26°, 33.35°, 35.01°, 35.52°, 36.51°, 37.70°, and 39.24°.
5 . The crystal form A of the compound of formula (I) according to claim 4 , wherein the crystal form A of the compound of formula (I) has an X-ray powder diffraction pattern basically as shown in FIG. 1 .
6 . The crystal form A of the compound of formula (I) according to claim 1 , wherein the crystal form A of the compound of formula (I) has a differential scanning calorimetry curve comprising an endothermic peak at 89.2±3° C.
7 . The crystal form A of the compound of formula (I) according to claim 6 , wherein the crystal form A of the compound of formula (I) has a DSC pattern basically as shown in FIG. 2 .
8 . The crystal form A of the compound of formula (I) according to claim 1 , wherein the crystal form A of the compound of formula (I) has a thermogravimetric analysis curve with a weight loss of 1.03% at 100±3° C.
9 . The crystal form A of the compound of formula (I) according to claim 8 , wherein the crystal form A of the compound of formula (I) has a TGA pattern basically as shown in FIG. 3 .
10 . A method for preventing a disease in a subject in need thereof, comprising administering an effective amount of the crystal form A of the compound of formula (I) according to claim 1 , the disease is liver cancer, prostate cancer, pancreatic cancer, or T-cell acute lymphoblastic leukemia.
11 . The method according to claim 10 , wherein the X-ray powder diffraction pattern of the crystal form A of the compound of formula (I) comprises characteristic diffraction peaks at the following 2θ angles: 8.25±0.20°, 13.27±0.20°, 15.19±0.20°, 16.43±0.20°, 17.94±0.20°, 19.21±0.20°, and 21.76±0.20°.
12 . The method according to claim 10 , wherein the X-ray powder diffraction pattern of the crystal form A of the compound of formula (I) comprises characteristic diffraction peaks at the following 2θ angles: 8.25±0.20°, 15.19±0.20°, 16.43±0.20°, 17.94±0.20°, 19.21±0.20°, 21.76±0.20°, 23.56±0.20°, and 26.66±0.20°.
13 . The method according to claim 10 , wherein the X-ray powder diffraction pattern of the crystal form A of the compound of formula (I) comprises characteristic diffraction peaks at the following 2θ angles: 8.25°, 12.56°, 12.89°, 13.27°, 15.19°, 16.01°, 16.43°, 17.60°, 17.94°, 19.21°, 19.91°, 20.21°, 20.52°, 21.25°, 21.76°, 23.02°, 23.56°, 24.71°, 25.12°, 25.88°, 26.66°, 27.10°, 27.43°, 27.84°, 28.38°, 29.13°, 30.01°, 30.83°, 31.69°, 32.26°, 33.35°, 35.01°, 35.52°, 36.51°, 37.70°, and 39.24°.